BLPG
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Blue Line Protection earns a Neutral rating, with a 48.5 composite score and low 1/5 conviction. Fundamentals provide the clearest support at 62.0, led by exceptional gross-margin performance, positive operating profitability, positive EBITDA, and stable financial condition. The regulatory pillar contributes a middling 49.0: a balanced domestic jurisdiction posture and no enforcement hits offset weak filing cadence. The market pillar scores 40.0 because institutional pricing feeds provide no available quote, limiting confirmation from trading behavior. Editorial contributes 30.0, reflecting no qualifying newsroom or brief activity in CIN newsroom coverage. The resulting profile combines credible operating economics with insufficient market visibility, limited disclosure recency, and no editorial momentum.
Licensed fundamentals data show year-over-year revenue contracted 9.1%, keeping the revenue-growth subscore at 40.9 despite stronger profitability measures. Gross margin reached approximately 62.4%, producing the maximum 100.0 gross-margin subscore, while the 3.68% operating margin supported a 79.8 operating-margin subscore. EBITDA totaled roughly $263,238 and net income was about $88,209, reinforcing positive profitability and a 90.0 cash-runway subscore. That strength is counterbalanced by a market capitalization near $494,926, which generated no contribution from the market-cap tier. Primary regulatory filings show no dated latest filing, no regulatory events during either the latest 90-day or 180-day periods, and no enforcement hits. Those inputs translate into a 25.0 cadence subscore and an 80.0 enforcement subscore, making disclosure frequency the principal regulatory constraint rather than adverse action.
The forward catalyst sits squarely within fundamentals, the strongest pillar. Blue Line Protection already converts a high proportion of revenue into gross profit and maintains positive operating margin, EBITDA, and net income, but declining sales prevent those economics from producing a stronger composite result. Revenue stabilization would validate the durability of the 62.4% gross margin, create a firmer base for operating leverage, and raise confidence beyond the current low-conviction Neutral stance. Market confirmation also remains constrained until institutional pricing feeds restore an observable quote, while fresher primary regulatory filings would improve transparency. The single most important signal to watch is a return to positive year-over-year revenue growth without material erosion in gross margin.
- Headquarters
- 5576 Offices Arizona 4328 E. Magnolia Street Phoenix, AZ 85034
- Phone
- 1-800-844-5576
- CEO
- Evan De***e
- SEC CIK
- 0001416697
- Website
- Company website
- Market cap
- $0.5M
- Enterprise value
- $1.4M
- Price to book
- 117.96
- Price to sales
- 0.12
- EV / EBITDA
- 2.73
- Revenue (TTM)
- $4.3M
- Gross profit (TTM)
- $2.7M
- EBITDA
- $263K
- Operating margin
- 3.7%
- Profit margin
- 2.1%
- Rev growth YoY
- -9.1%
- Return on equity
- 0.0%
- Return on assets
- 7.0%
- Shares outstanding
- 8.3M
- Insider ownership
- 1.0%
- Beta
- 1.28
- Full-time employees
- 35
- GICS sector
- Industrials
- GICS industry
- Security & Protection Services
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for BLPG (BLPG)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for BLPG (BLPG), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for BLPG are maintained by Cannabis Investor News and refreshed throughout the trading day.